D. G. Kieback

1.4k citations

31 papers · 946 indexed · h-index 14

Cancer Research top 5%
- Breast Cancer Treatment Studies 10
Oncology top 5%
- HER2/EGFR in Cancer Research 7
- Bone health and treatments 3
- Cancer Treatment and Pharmacology 3
Genetics top 5%
- Estrogen and related hormone effects 15
Obstetrics and Gynecology top 10%
- Endometrial and Cervical Cancer Treatments 6
Pulmonary and Respiratory Medicine top 10%
Rheumatology
- Pelvic floor disorders treatments 3
Surgery
- Anorectal Disease Treatments and Outcomes 3

Co-authors: Annette Hasenburg Peyman Hadji John M.S. Bartlett Christos Markopoulos Daniel Rea Caroline Seynaeve Hein Putter E.T.M. Hille
Cited by: Cancer Research Oncology Genetics
Journals: Journal of Clinical Oncology (7 papers)Gynecologic Oncology (2 papers)Annals of Oncology (2 papers)
Partner nations: Germany United Kingdom Netherlands

In The Last Decade

D. G. Kieback

31 papers receiving 932 citations

Peers

Countries citing papers authored by D. G. Kieback

Since Specialization

Citations

This map shows the geographic impact of D. G. Kieback's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. G. Kieback with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. G. Kieback more than expected).

Fields of papers citing papers by D. G. Kieback

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. G. Kieback. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. G. Kieback. The network helps show where D. G. Kieback may publish in the future.

Co-authorship network

The 25 scholars most cited alongside D. G. Kieback, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with D. G. Kieback Line = papers co-authored together D. G. Kieback links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Bilateral Sacrospineous Colposupension in the treatment of female genital prolapse: Risk-Benefit Considerations and Six Months Follow-up 硫安工業復興会議,Lee JeongSuk,A. Wagner,C. Roffe,D. G. Kieback	2021	2
2	Molecular stratification of early breast cancer identifies drug targets to drive stratified medicine npj Breast Cancer ·Jane Bayani,Cindy Q. Yao,Soumya Mishra,Fu Yan,Syed Haider,Alister D’Costa,Cassandra Brookes,Cornelis J.�H. van de Velde,Annette Hasenburg,D. G. Kieback,Christos Markopoulos,Luc Dirix,Caroline Seynaeve,Daniel Rea,Paul C. Boutros,John M.S. Bartlett	2017	16
3	Copy-number and targeted sequencing analyses to identify distinct prognostic groups: Implications for patient selection to targeted therapies amongst anti-endocrine therapy resistant early breast cancers. Journal of Clinical Oncology ·Jane Bayani,Elizabeth Kornaga,直博佐波古,Gun Ho Jang,Irina Kalatskaya,Quang M. Trinh,Cindy Q. Yao,Julie Livingstone,Annette Hasenburg,D. G. Kieback,Christos Markopoulos,Luc Dirix,Paul C. Boutros,Melanie Spears,Lincoln Stein,Daniel Rea,John M.S. Bartlett	2017	1
4	Do type 1 receptor tyrosine kinases inform treatment choice? A prospectively planned analysis of the TEAM trial British Journal of Cancer ·John M.S. Bartlett,Cassandra Brookes,Tammy Piper,Cornelis J.�H. van de Velde,Deborah Stocken,L Di Renzo,Annette Hasenburg,Soumya Mishra,D. G. Kieback,Hein Putter,Christos Markopoulos,Sujin Hyun,E. Mallon,Luc Dirix,Caroline Seynaeve,Daniel Rea	2013	6
5	Effects of exemestane and tamoxifen on hormone levels within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) Trial: results of a German substudy Climacteric ·Peyman Hadji,Liwen Xu,Thomas Bauer,S Dudine,Annette Hasenburg,D. G. Kieback	2012	13
6	Compliance, analgesic use and side-effect protection within a German cohort of the TEAM trial. PubMed ·H. Platta,Meike Becker,Peyman Hadji,D. G. Kieback,Annette Hasenburg	2012	4
7	Validation of IHC4 algorithms for prediction of risk of recurrence in early breast cancer using both conventional and quantitative IHC approaches. Journal of Clinical Oncology ·Jason Christiansen,John M.S. Bartlett,Mark Gustavson,David L. Rimm,Tammy Robson,Cornelis J.�H. van de Velde,Annette Hasenburg,D. G. Kieback,Hein Putter,Christos Markopoulos,Luc Dirix,Caroline Seynaeve,Daniel Rea	2012	7
8	Correlation of treatment-emergent adverse events and clinical response to endocrine therapy in early breast cancer: a retrospective analysis of the German cohort of TEAM Annals of Oncology ·Peyman Hadji,D. G. Kieback,S Dudine,Annette Hasenburg,M. Ziller	2012	16
9	Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial The Lancet ·Cornelis JH van de Velde,Daniel Rea,Caroline Seynaeve,Hein Putter,Annette Hasenburg,Jean-Michel Vannetzel,Robert Paridaens,Christos Markopoulos,Yasuo Hozumi,E.T.M. Hille,D. G. Kieback,Lina Asmar,Jan Smeets,J.W.R. Nortier,Peyman Hadji,John M.S. Bartlett,Stephen E. Jones	2011	264
10	Estrogen Receptor and Progesterone Receptor As Predictive Biomarkers of Response to Endocrine Therapy: A Prospectively Powered Pathology Study in the Tamoxifen and Exemestane Adjuvant Multinational Trial Journal of Clinical Oncology ·John M.S. Bartlett,Cassandra Brookes,Tammy Robson,Cornelis J.�H. van de Velde,Lucinda Billingham,Fiona Campbell,Margaret Grant,Annette Hasenburg,E.T.M. Hille,Charlene Kay,D. G. Kieback,Hein Putter,Christos Markopoulos,Elma Meershoek‐Klein Kranenbarg,Elizabeth A. Mallon,Luc Dirix,Caroline Seynaeve,Daniel Rea	2011	142
11	Endometrial effects of exemestane compared to tamoxifen within the Tamoxifen Exemestane Adjuvant Multicenter (TEAM) trial: Results of a prospective gynecological ultrasound substudy Gynecologic Oncology ·D. G. Kieback,Nadia Harbeck,Wolfgang Bauer,Peyman Hadji,George DeLullo,Andiko Pradana,Annette Hasenburg	2010	14
12	Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy Annals of Oncology ·Peyman Hadji,M. Ziller,D. G. Kieback,W. Dornoff,Raymond Tremolieres,Andiko Pradana,Joachim Kuck,F. Melchert,Annette Hasenburg	2009	52
13	The effect of exemestane or tamoxifen on markers of bone turnover: Results of a German sub-study of the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial The Breast ·Peyman Hadji,M. Ziller,D. G. Kieback,Andiko Pradana,Matthias Kalder,Joachim Kuck,Annette Hasenburg	2009	42
14	A prospectively planned pathology study within the TEAM trial confirms that progesterone receptor expression is prognostic but is not predictive for differential response to exemestane versus tamoxifen. Cancer Research ·JMS Bartlett,Cassandra Brookes,Lucinda Billingham,Fiona Campbell,Margaret Grant,Annette Hasenburg,E.T.M. Hille,Charlene Kay,D. G. Kieback,Christos Markopoulos,Elma Meershoek‐Klein Kranenbarg,E. Mallon,Robert Paridaens,Tammy Robson,Caroline Seynaeve,CJH van de Velde,Daniel Rea	2009	5
15	Midline intravaginal slingplasty for treatment of urinary stress incontinence: results of an independent audit up to 2 years after surgery International Urogynecology Journal ·Marga M. IJland,Dagmar‐C. Fischer,D. G. Kieback,Abdulazizov Abdullokh Abdukakhkhar Ugli,Bruce Farnsworth	2005	6
16	Functional characterization of somatic point mutations of the human estrogen receptor α (hERα) in adenomyosis uteri Molecular Human Reproduction ·Martin K. Oehler,Holger Greschik,Dagmar‐C. Fischer,Xiaowen Tong,F. IORDACHE,D. G. Kieback	2004	17
17	Evaluation of Patients after Extraperitoneal Lymph Node Dissection and Subsequent Radiotherapy for Cervical Cancer Gynecologic Oncology ·Annette Hasenburg,Joseph K. Salama,J Li,Toy Lisa,Joseph Chiu,D. G. Kieback	2002	34
18	Topotecan Chemotherapy in Patients with Breast Cancer and Brain Metastases: Results of a Pilot Study Oncology Research and Treatment ·C. Oberhoff,D. G. Kieback,Rachel Würstlein,孟鑫,Jalid Sehouli,田辺安一,J. Hilfrich,Н.Ю. Яськова,Gϋnter von Minckwitz,H. J. Staab,A. E. Schindler	2001	81
19	Comparative Evaluation of Seven Cell Collection Devices for Cervical Smears Acta Cytologica ·Petra Kohlberger,Josefine Stani,G. Gitsch,D. G. Kieback,G. Breitenecker	1999	17
20	[Sexual development: development of secondary sex characteristics--Tanner stages 25 years later]. PubMed ·Fritz Karl Beller,A Borsòs,D. G. Kieback,C. Discala,Lee R. MacDonald	1991	1

About D. G. Kieback

D. G. Kieback is a scholar working on Obstetrics and Gynecology, Cancer Research, Oncology, Genetics and Reproductive Medicine, having authored 31 papers that have together received 946 indexed citations. Recurring topics across this work include Estrogen and related hormone effects (15 papers), Breast Cancer Treatment Studies (10 papers), HER2/EGFR in Cancer Research (7 papers), Endometrial and Cervical Cancer Treatments (6 papers), Bone health and treatments (3 papers), Pelvic floor disorders treatments (3 papers), Anorectal Disease Treatments and Outcomes (3 papers) and Cancer Treatment and Pharmacology (3 papers). The work is most often cited by research in Cancer Research (393 citations), Oncology (530 citations), Genetics (372 citations), Obstetrics and Gynecology (81 citations) and Pulmonary and Respiratory Medicine (248 citations). D. G. Kieback has collaborated with scholars based in Germany, United Kingdom and Netherlands. Frequent co-authors include Annette Hasenburg, Peyman Hadji, John M.S. Bartlett, Christos Markopoulos, Daniel Rea, Caroline Seynaeve, Hein Putter, E.T.M. Hille, Luc Dirix and Cornelis J.�H. van de Velde. Their work appears in journals such as Journal of Clinical Oncology, Gynecologic Oncology, Annals of Oncology, Cancer Research and International Journal of Gynecological Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact